Srinivas Akkaraju bought $1.2M of KLRS
director, owner at Allovir, Inc.. 244,300 shares at an average of $4.83, traded May 20, 2026, filed May 22, 2026.
Score components
- +15RoleDirector
- +25Trade size$1.2M at market
- +3Relative to holdingsHoldings up 12%
- +8Price context56% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-26-000532, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 20, 2026 | POpen-market purchase Common Stockindirect: By Samsara Opportunity Fund, L.P. | +244,300 | $4.83 | $1.2M | 2,224,147 | May 22, 2026 |
| May 20, 2026 | JOther Common Stockindirect: By Samsara BioCapital, L.P. | -66,906 | $0.00 | $0 | 10,657,028 | May 22, 2026 |
| May 20, 2026 | JOther Common Stockindirect: By Samsara BioCapital GP, LLC | +14,937 | $0.00 | $0 | 14,937 | May 22, 2026 |
| May 20, 2026 | JOther Common Stockindirect: By Samsara BioCapital Partners, L.P. | +4,471 | $0.00 | $0 | 19,408 | May 22, 2026 |
Related signals
Other insiders at Allovir, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | KLRSsell Allovir, Inc. | Brett R Hagen Chief Accounting Officer | $13k 1,915 shares | -100% | |
| 46Moderate | KLRSbuy Allovir, Inc. | Srinivas Akkaraju director, owner | $5.0M 479,847 shares | +32% | |
| 25Weak | KLRSsell Allovir, Inc. | Brett R Hagen Chief Accounting Officer | $8,135 907 shares | -32% | |
| 30Weak | Allovir, Inc. | Edward Miller General Counsel | $1,068 106 shares | -2% | |
| 30Weak | Allovir, Inc. | Brett R Hagen Chief Accounting Officer | $967 96 shares | -3% | |
| 30Weak | Allovir, Inc. | Vikas Sinha See Remarks | $3,053 303 shares | -1% | |
| 30Weak | Allovir, Inc. | Vikas Sinha See Remarks | $1,226 129 shares | -0% | |
| 30Weak | Allovir, Inc. | Brett R Hagen Chief Accounting Officer | $342 36 shares | -1% | |
| 30Weak | Allovir, Inc. | Edward Miller General Counsel | $494 52 shares | -1% | |
| 30Weak | Allovir, Inc. | Vikas Sinha See Remarks | $431 979 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.